Advanced Medical Solutions GroupCHIX:AMSL +14.17%93 EBITDA Margin % is 18.81% as of Dec. 2025, which is 32% below its 10-year median of 27.57. GuruFocus rates CHIX:AMSL with a GF Score™ of 93/100 and a GF Value™ of £3.71 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Advanced Medical Solutions Group ranks better than 73.9% on this metric.
Advanced Medical Solutions Group (CHIX:AMSl) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Advanced Medical Solutions Group EBITDA Margin % Related Terms
Advanced Medical Solutions Group EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Advanced Medical Solutions Group EBITDA Margin % Chart
CHIX:AMSL vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Advanced Medical Solutions Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Advanced Medical Solutions Group EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Advanced Medical Solutions Group's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Advanced Medical Solutions Group's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Advanced Medical Solutions Group (CHIX:AMSL) has a EBITDA Margin % of 18.81% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Advanced Medical Solutions Group and its competitors. This is 32% below median its historical median of 27.57. Over the past decade, Advanced Medical Solutions Group's EBITDA Margin % has ranged from 16.63 to 32.03. According to the industry distribution chart, Advanced Medical Solutions Group ranks #213 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 26.1%.
Is Advanced Medical Solutions Group's EBITDA Margin % too high?
Advanced Medical Solutions Group's current EBITDA Margin % of 18.81% is 32% below median its 10-year median of 27.57. Over the past 10 years, this metric has ranged from a low of 16.63 to a high of 32.03. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Advanced Medical Solutions Group's value of 18.81% is 151.6% above this industry median. Based on the distribution chart, Advanced Medical Solutions Group ranks #213 out of 816 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Advanced Medical Solutions Group has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Advanced Medical Solutions Group's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Advanced Medical Solutions Group ranks #213 out of 816 companies for EBITDA Margin %. This puts Advanced Medical Solutions Group in the upper half of its industry. The industry median EBITDA Margin % is 7.48. Advanced Medical Solutions Group's value of 18.81% is 151.6% above this benchmark. Historically, Advanced Medical Solutions Group's own EBITDA Margin % has ranged from 16.63 to 32.03 over the past decade. While the company's 10-year median is 27.57 vs. the industry median of 7.48, Advanced Medical Solutions Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Advanced Medical Solutions Group's current EBITDA Margin % of 18.81% is 151.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Advanced Medical Solutions Group and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Advanced Medical Solutions Group's current EBITDA Margin % is 18.81%, which is 32% below median its own 10-year median of 27.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Medical Solutions Group stock overvalued right now?
Based on GuruFocus' analysis, Advanced Medical Solutions Group (CHIX:AMSL) is currently considered Modestly Undervalued. The stock's GF Value™ is £3.71, compared to a current price of £2.78 — trading 25.1% below its estimated fair value. The current EBITDA Margin % is 18.81%, which is 32% below median its 10-year median of 27.57 and 151.6% above the Medical Devices & Instruments industry median of 7.48. Advanced Medical Solutions Group's overall GF Score™ is 93/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Advanced Medical Solutions Group (CHIX:AMSL), the current EBITDA Margin % is 18.81% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Advanced Medical Solutions Group (CHIX:AMSL) Overvalued in 2026?
Based on GuruFocus' analysis, Advanced Medical Solutions Group stock appears to be undervalued.
The current stock price of £2.78 is trading 25.1% below its estimated GF Value™ of £3.71.
GuruFocus considers Advanced Medical Solutions Group to be Modestly Undervalued.
Key valuation signals for CHIX:AMSL:
EBITDA Margin %: 18.81% (32% below median its 10-year median of 27.57)
GF Value™: £3.71 vs. price of £2.78 (25.1% below fair value)
Industry Position: 151.6% above the Medical Devices & Instruments median (#213 of 816)
No single metric tells the full story. See the CHIX:AMSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Advanced Medical Solutions Group Business Description
Advanced Medical Solutions Group PLC is engaged in developing and manufacturing wound-care products for other healthcare manufacturers. AMS' key branded products include the ActivHeal franchise of hydrogel, hydrocolloid, foam, and alginate wound dressings. The firm also manufactures and markets a suite of branded products in surgical use, including the LiquiBand franchise for tissue adhesion and the Resorba line of sutures and collagen-based products for tissue repair. The company's segment includes: Surgical and Woundcare, of which the Surgical segment derives maximum revenue. Geographically, the company operates in the United Kingdom, Germany, France, the rest of Europe, the United States of America, and the rest of the world.
93GF Score
Get the complete analysis for CHIX:AMSL
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:AMSL has been successfully added to your 
